Poster Abstracts 13Th International Conference on Myasthenia Gravis and Related Disorders Abstract List
Total Page:16
File Type:pdf, Size:1020Kb
13th International Conference on Myasthenia Gravis and Related Disorders POSTER SESSION MAY 15, 2017 | 6:00 PM New York Marriott Downtown Basic Science and Animal Models 1. Sonia Berrih-Aknin, DSc, Preconditioned Mesenchymal Stem Cells Treat Myasthenia Gravis in a Humanized Preclinical Model 2. Michelangelo Cao, MD, Specificity of Shp2 Inhibition on Acetylcholine Receptor Clustering 3. Hakan Cetin, MD, Fetal and Adult Acetylcholine Receptor Function and the Impact of Receptor Clustering 4. Leslie Jacobson, BSc, Dphil, AChR-antibody Mediated Arthrogryposis: Inhibition of Placental Transfer in a Mouse Model Protects the Fetus 5. Linda Kusner, PhD, Preclinical Pilot Study of Alpha-fetoprotein on Moderation of MG Weakness 6. Konstantinos Lazaridis, PhD, Antigen-specific Therapeutic Immunoadsorption Results in Amelioration of Experimental MG Symptoms 7. Christopher Meriney, BS, Lambert-Eaton Myasthenic Syndrome: Passive Transfer to Mice, Active Zone Structure-function Relationships, and Novel Treatment Strategies 8. David P. Richman, MD, Analysis of Muscle Wasting in an Acute Severe Model of Muscle-specific Kinase Antibody Myasthenia Gravis 9. Kazuhiro Shigemoto, MD, Mouse Model of Lrp4-MG 10. Jie Song, MD, ROCK Inhibitor Suppresses Experimental Autoimmune Myasthenia Gravis by Inhibiting Th1, Th17 and B-cells 11. Armineh Issakhanian Stoner, MS, The Potential Role of Anti-Lrp4 Autoantibodies in the pathogenesis of Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS) 12. Erdem Tüzün, MD, MuSK-binding Peripheral B-cells as Biomarker for MuSK-Myasthenia Gravis 1 | Poster Abstracts 13th International Conference on Myasthenia Gravis and Related Disorders Abstract List 13. Adi Vaknin-Dembinsky, MD, PhD, Exacerbation of EAMG by NMO Antibodies or Aquaporin 4 Peptide 14. Richard Webster, PhD, Electrophysiological Characterisation of a Mouse Model of DOK7 Congenital Myasthenic Syndrome and Treatment with Salbutamol Case Report 15. Edward W. Bahou, MD, Unusual Facial Myokymia in a Patient with Ganglionic Acetylcholine Receptor Antibodies 16. Juhyeon Kim, MD, PhD, Exacerbation of Myasthenia Gravis in Thymic Cancer Patients Treated with Pembrolizumab: Three Case Reports 17. Araya Puwanant, MD, Myasthenia Gravis and Immune Checkpoint Inhibitors: Balancing Treatment Efficacy and Complications in Cancer Immunotherapies Clinical 18. Silvia Bonanno, MD, MuSK MG Patients Showed a Positive Response to Amifampridine Phosphate in a Randomized, Placebo-Controlled, Crossover Study 19. Elena Cortes-Vicente, MD, and Aditya Kumar, MD, Comparison of Rituximab Treatment Regimens in MuSK Antibody Positive Myasthenia Gravis 20. Mazen Dimachkie, MD, FAAN, FANA, Challenges in a Multicenter Study of Subcutaneous Immunoglobulin in Myasthenia Gravis 21. Daniel B. Drachman, MD, Pilot Trial of Abatacept in Myasthenia Gravis Patients Inadequately Responsive to Conventional Immunotherapy 22. Josep Gamez, MD, PhD, Intravenous Immunoglobulin as Monotherapy for Myasthenia Gravis during Pregnancy 23. Giulia Greco, MD, Very Late-onset Non-Thymomatous and Thymomatous Myasthenia Gravis (MG) Are Associated with Different HLA Class II Alleles 24. Jeffrey T. Guptill, MD, Comparative Effectiveness Research to Advance Treatment of Myasthenia Gravis 25. Charlene Hafer-Macko, MD, Walking Away from the Fatigue and Low Functional and Metabolic Capacity in Myasthenia Gravis 26. Kazuo Iwasa, MD, PhD, Correlations Between the Time Trends of Anti-acetylcholine Receptor Antibody Titer Variation in Myasthenia Gravis and the Incidence of Mycoplasma and Influenza Infections 27. Elzbieta Klimiec, MD, Thymus Radiological-pathological Correlations in Myasthenia Gravis — the Relevance in Clinical Practice 2 | Poster Abstracts 13th International Conference on Myasthenia Gravis and Related Disorders Abstract List 28. Arturo Leis, MD, West Nile Virus (WNV) Induces a Prolonged Pro-inflammatory State That May Promote Myasthenia Gravis (MG) 29. Xiao Xi Liu, MD, Hepatitis B Virus Reactivation in Myasthenia Gravis Patients with Immunosuppressive Treatments 30. YueXun Liu, MD, MS, Therapeutic Potential of Docetaxelpluscisplatin Chemotherapy in Myasthenia Gravis: Clinical Analysis of Patients with Thymoma-associated Myasthenia Gravis 31. Tahseen Mozaffar, MD, INSIGHTS: Analysis of Responsiveness of IVIG in Patients with Myasthenia Gravis 32. Jay S. Raval, MD, Association of Total Serum Immunoglobulin G (IgG) Concentrations during Therapeutic Plasma Exchange (TPE) Therapy and Myasthenia Gravis (MG) Persistence 33. Elisabeth Strijbos, MD, Efficacy and Safety of Tetanus Revaccination in Autoimmune Myasthenia Gravis 34. Peter Ulrichts, PhD, ARGX-113, A Novel Fc-based Approach for Antibody-induced Pathologies such as Myasthenia Gravis 35. Elisabet Westerberg, MD, Myasthenia Gravis Patients Respond with Muscular Improvement to Physical Exercise 36. Fritz Zimprich, MD, PhD, Iodinated Contrast Agents in Patients with Myasthenia Gravis: a Retrospective Cohort Study Clinical Samples 37. Claudia Barzago, PhD, Altered MicroRNA Expression in Myasthenia Gravis Thymus: Possible Contribution to the Pathogenesis 38. Derrick Blackmore, BSc, Subcutaneous Immunoglobulin Therapy in Patients with Myasthenia Gravis Exacerbation: Results of a Prospective, Open-label, Phase 3 Study (SCIg-MG) 39. Paola Cavalcante, PhD, Presence of Epstein-Barr Virus in B-cells of Myasthenia Gravis Thymoma: Innocent Bystander or Autoimmunity Mediator? 40. Pei Chen, MD, More Mature/active Dendritic Cells in the Hyperplasia Thymuses of Myasthenia Gravis Patients 41. Mélanie A. Cron, MSc, Role of miR-150 in Autoimmune Myasthenia Gravis 42. Nadine Dragin, PhD, AhR Activation May Regulate Expression of Pro-inflammatory Factors in Thymuses of AChR+ Myasthenia Gravis Patients 43. Alejandro Gomez, PhD, Autoantibody Capture through Barcode-based Sequencing of Single Cells in Myasthenia Gravis 3 | Poster Abstracts 13th International Conference on Myasthenia Gravis and Related Disorders Abstract List 44. Hao Huang, MD, Distribution and Characteristics of Dendritic Cells Subtypes in Hyperplastic Thymus in Patients with MG 45. Michala Jakubíková, MD, PhD, Two-year Outcome of Thymectomy with or without Immunosuppressive Treatment in Nonthymomatous Myasthenia Gravis and its Effect on Regulatory T-cells 46. Inga Koneczny, DPhil, IgG4 Autoantibodies against Muscle-specific Kinase Undergo Fab-arm Exchange in Myasthenia Gravis Patients 47. Aditya Kumar, MD and Panos Stathopoulos, MD, PhD, Identifying the B Cell Subsets that Contribute to Autoantibody Production in Myasthenia Gravis 48. M Isabel Leite, MD, DPhil, Serum Acetylcholine-receptor Antibody Concentrations in 71 patients Included in the Randomized Trial of Thymectomy in Myasthenia Gravis (MGTx) 49. Rozen Le Panse, PhD, Skeletal Muscle Regeneration is Impaired in Response to Acute Injury in Myasthenia Gravis 50. Marina Mane-Damas, MSc, Targeting Plasma Cells with Proteasome Inhibitors for Treatment of Myasthenia Gravis 51. Angelina Maniaol, MD, PhD, Agrin Antibodies in Myasthenia Gravis — What is Their Clinical Relevance? 52. Liis Sabre, MD, PhD, Reduction of Extracellular MiR-150-5p Levels Accompanies Improved Disease Severity in Myasthenia Gravis Patients 24 Months Post-thymectomy 53. Manjisth Sengupta, PhD, MicroRNA and M-RNA Expression Study in Ectopic Germinal Centers of Myasthenia Gravis Thymus 54. Kamal Shouman, MD, Serum Creatine Kinase Levels in Myasthenia Gravis 55. Betty Soliven, MD, Impaired Regulatory B cells in Myasthenia Gravis 56. Vuslat Yilmaz, PhD, Altered Number and Functionality of Regulatory B Cells in Myasthenia Gravis Patient Congenital Myasthenia Syndromes 57. Judith Cossins, BA, DPhil, Mutation in a Nuclear Envelope Protein Causes a Novel Congenital Myasthenic Syndrome 58. Susan Maxwell, MSc, Congenital Myasthenic Syndrome due to Mutations in Agrin 59. Mirela Daniela Panea, MSc, Pathogenic Mechanisms of RAPSN Mutations in Congenital Myasthenic Syndromes 4 | Poster Abstracts 13th International Conference on Myasthenia Gravis and Related Disorders Abstract List 60. Pedro M. Rodríguez Cruz, MD, MSc, Mutations in GMPPB Can Combine a Myasthenic Syndrome with a Myopathy 61. Xin-Ming Shen, PhD, Novel Synaptobrevin-1 Mutation Causes Fatal Congenital Myasthenic Syndrome Management Diagnostic 62. Sneha Alaparthi, BS and Rahul Anil, MD, Exploring Outcomes and Characteristics of Myasthenia Gravis: Rationale, Aims and Design of Registry — The EXPLORE MG Registry 63. Paolo Emilio Alboini, MD, Cognitive Impairment in Myasthenia Gravis with MuSK Antibodies 64. Carolina Barnett-Tapia, MD, PhD, Fatigue in Patients With Myasthenia Gravis: Impact on Quality of Life and Responsiveness to Prednisone and Immunomodulation 65. Aisling S. Carr, MRCP Neurol., PhD, A Serological and Clinical Epidemiological Study of the Myasthenia Gravis in Northern Ireland 66. Valentina Damato, MD, Clinical and Serological Characteristics of Patients with Double Seronegative Myasthenia Gravis 67. Robert H. de Meel, MD, Ocular Weakness Patterns in Myasthenia Gravis 68. Anna De Rosa, MD, Thymoma-associated Myasthenia Gravis: Clinical and Serological Features of Pisa’s Cohort 69. Wei Fang, PhD, Epidemiology of Myasthenia Gravis in Southern China — Estimates Using Hospital and Insurance Records 70. Maria Elena Farrugia, DPhil, MD, FRCP(E), Management of Ocular Myasthenia Gravis in Glasgow 71. Asger Frost, PhD, Characteristics of Long-time Patients with Myasthenia Gravis in a Danish Population 72. Raffaele Iorio, MD, PhD, Neurological Autoimmunity Associated with Thymoma: Beyond Myasthenia Gravis 73. Hans Katzberg, MD,